{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T08:40:05Z","timestamp":1751791205666,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002642","name":"Korea university","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-08417-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:44:10Z","timestamp":1751399050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran"],"prefix":"10.1038","volume":"15","author":[{"given":"Jong-Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Yoon","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"8417_CR1","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2146\/ajhp100348","volume":"68","author":"ML Blommel","year":"2011","unstructured":"Blommel, M. L. & Blommel, A. L. Dabigatran etexilate: A novel oral direct thrombin inhibitor. Am. J. Health Syst. Pharm. 68, 1506\u20131519. https:\/\/doi.org\/10.2146\/ajhp100348 (2011).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"8417_CR2","unstructured":"Cid-Conde, L., L\u00f3pez-Castro, J. & Liu, T. (IntechOpen) (2013)."},{"key":"8417_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1160\/TH07-03-0183","volume":"98","author":"W Wienen","year":"2007","unstructured":"Wienen, W., Stassen, J. M., Priepke, H., Ries, U. J. & Hauel, N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor Dabigatran and its orally active prodrug, Dabigatran etexilate. Thromb. Haemost. 98, 155\u2013162 (2007).","journal-title":"Thromb. Haemost"},{"key":"8417_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bcp.2016.09.003","volume":"119","author":"J Shi","year":"2016","unstructured":"Shi, J. et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem. Pharmacol. 119, 76\u201384. https:\/\/doi.org\/10.1016\/j.bcp.2016.09.003 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"8417_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/dmd.113.054353","volume":"42","author":"SC Laizure","year":"2014","unstructured":"Laizure, S. C., Parker, R. B., Herring, V. L. & Hu, Z. Y. Identification of carboxylesterase-dependent Dabigatran etexilate hydrolysis. Drug Metab. Dispos. 42, 201\u2013206. https:\/\/doi.org\/10.1124\/dmd.113.054353 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"8417_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386\u2013399. https:\/\/doi.org\/10.1124\/dmd.107.019083 (2008).","journal-title":"Drug Metab. Dispos."},{"key":"8417_CR7","doi-asserted-by":"publisher","first-page":"e00593","DOI":"10.1002\/prp2.593","volume":"8","author":"X Li","year":"2020","unstructured":"Li, X. et al. Bioequivalence and pharmacodynamics of a generic Dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions. Pharmacol. Res. Perspect. 8, e00593. https:\/\/doi.org\/10.1002\/prp2.593 (2020).","journal-title":"Pharmacol. Res. Perspect."},{"key":"8417_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40262-019-00776-y","volume":"58","author":"D Moj","year":"2019","unstructured":"Moj, D. et al. A comprehensive Whole-Body physiologically based Pharmacokinetic model of Dabigatran etexilate, Dabigatran and Dabigatran glucuronide in healthy adults and renally impaired patients. Clin. Pharmacokinet. 58, 1577\u20131593. https:\/\/doi.org\/10.1007\/s40262-019-00776-y (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"8417_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor Dabigatran etexilate. Clin. Pharmacokinet. 47, 285\u2013295. https:\/\/doi.org\/10.2165\/00003088-200847050-00001 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"8417_CR10","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1124\/dmd.110.033696","volume":"38","author":"T Ebner","year":"2010","unstructured":"Ebner, T., Wagner, K. & Wienen, W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and Pharmacological activity. Drug Metab. Dispos. 38, 1567\u20131575. https:\/\/doi.org\/10.1124\/dmd.110.033696 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"8417_CR11","doi-asserted-by":"publisher","first-page":"114220","DOI":"10.1016\/j.jpba.2021.114220","volume":"203","author":"IH Park","year":"2021","unstructured":"Park, I. H. et al. Development and validation of LC-MS\/MS method for simultaneous determination of Dabigatran etexilate and its active metabolites in human plasma, and its application in a Pharmacokinetic study. J. Pharm. Biomed. Anal. 203, 114220. https:\/\/doi.org\/10.1016\/j.jpba.2021.114220 (2021).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"8417_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jchromb.2015.02.042","volume":"989","author":"EG Nouman","year":"2015","unstructured":"Nouman, E. G., Al-Ghobashy, M. A. & Lotfy, H. M. Development and validation of LC-MSMS assay for the determination of the prodrug Dabigatran etexilate and its active metabolites in human plasma. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 989, 37\u201345. https:\/\/doi.org\/10.1016\/j.jchromb.2015.02.042 (2015).","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"8417_CR13","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1177\/0091270008324179","volume":"48","author":"J Stangier","year":"2008","unstructured":"Stangier, J., St\u00e4hle, H., Rathgen, K., Roth, W. & Shakeri-Nejad, K. Pharmacokinetics and pharmacodynamics of Dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J. Clin. Pharmacol. 48, 1411\u20131419. https:\/\/doi.org\/10.1177\/0091270008324179 (2008).","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl 1","key":"8417_CR14","doi-asserted-by":"publisher","first-page":"9s","DOI":"10.1177\/1076029609343004","volume":"15","author":"J Stangier","year":"2009","unstructured":"Stangier, J. & Clemens, A. Pharmacology, pharmacokinetics, and pharmacodynamics of Dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost. 15 (Suppl 1), 9s\u201316s. https:\/\/doi.org\/10.1177\/1076029609343004 (2009).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"8417_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier, J., Rathgen, K., St\u00e4hle, H. & Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral Dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49, 259\u2013268. https:\/\/doi.org\/10.2165\/11318170-000000000-00000 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"8417_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier, J., St\u00e4hle, H., Rathgen, K. & Fuhr, R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor Dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 47, 47\u201359. https:\/\/doi.org\/10.2165\/00003088-200847010-00005 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"8417_CR17","first-page":"264","volume":"14","author":"M Balaji","year":"2014","unstructured":"Balaji, M., Srinivasarao, V., Rao, K. & Ch Appa, R. K. A new and stability indicating liquid chromatographic method for the determination of Dabigatran in bulk drug and pharmaceutical dosage form. Anal. Chem. Indian J. 14, 264\u2013273 (2014).","journal-title":"Anal. Chem. Indian J."},{"key":"8417_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020257","author":"JM Kim","year":"2022","unstructured":"Kim, J. M. et al. Dabigatran acylglucuronide, the major metabolite of dabigatran, shows a weaker anticoagulant effect than dabigatran. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics14020257 (2022).","journal-title":"Pharmaceutics"},{"key":"8417_CR19","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","volume":"121","author":"F Schiele","year":"2013","unstructured":"Schiele, F. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121, 3554\u20133562. https:\/\/doi.org\/10.1182\/blood-2012-11-468207 (2013).","journal-title":"Blood"},{"key":"8417_CR20","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1161\/circulationaha.115.019628","volume":"132","author":"JW Eikelboom","year":"2015","unstructured":"Eikelboom, J. W., Quinlan, D. J., van Ryn, J. & Weitz, J. I. Idarucizumab: the antidote for reversal of Dabigatran. Circulation 132, 2412\u20132422. https:\/\/doi.org\/10.1161\/circulationaha.115.019628 (2015).","journal-title":"Circulation"},{"key":"8417_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1477-9560-3-16","volume":"3","author":"GT Gerotziafas","year":"2005","unstructured":"Gerotziafas, G. T. et al. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb. J. 3, 16. https:\/\/doi.org\/10.1186\/1477-9560-3-16 (2005).","journal-title":"Thromb. J."},{"key":"8417_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1538-7836.2010.03766.x","volume":"8","author":"L Ay","year":"2010","unstructured":"Ay, L. et al. Thrombin generation in morbid obesity: significant reduction after weight loss. J. Thromb. Haemost. 8, 759\u2013765. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03766.x (2010).","journal-title":"J. Thromb. Haemost"},{"key":"8417_CR23","doi-asserted-by":"publisher","first-page":"e2016014","DOI":"10.4084\/mjhid.2016.014","volume":"8","author":"E Holm","year":"2016","unstructured":"Holm, E., Zetterberg, E., L\u00f6vdahl, S. & Berntorp, E. Patients referred for bleeding symptoms of unknown cause: does evaluation of thrombin generation contribute to diagnosis?? Mediterr. J. Hematol. Infect. Dis. 8, e2016014. https:\/\/doi.org\/10.4084\/mjhid.2016.014 (2016).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"8417_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1389450118666170925155943","volume":"19","author":"F Cortese","year":"2018","unstructured":"Cortese, F. et al. Idarucizumab: what should we know?? Curr. Drug Targets. 19, 81\u201388. https:\/\/doi.org\/10.2174\/1389450118666170925155943 (2018).","journal-title":"Curr. Drug Targets"},{"key":"8417_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/s0140-6736(15)60732-2","volume":"386","author":"S Glund","year":"2015","unstructured":"Glund, S. et al. Safety, tolerability, and efficacy of Idarucizumab for the reversal of the anticoagulant effect of Dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386, 680\u2013690. https:\/\/doi.org\/10.1016\/s0140-6736(15)60732-2 (2015).","journal-title":"Lancet"},{"key":"8417_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1160\/th14-12-1080","volume":"113","author":"S Glund","year":"2015","unstructured":"Glund, S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to Dabigatran. Thromb. Haemost. 113, 943\u2013951. https:\/\/doi.org\/10.1160\/th14-12-1080 (2015).","journal-title":"Thromb. Haemost"},{"key":"8417_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajem.2016.09.050","volume":"34","author":"PA Reilly","year":"2016","unstructured":"Reilly, P. A., van Ryn, J., Grottke, O., Glund, S. & Stangier, J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am. J. Emerg. Med. 34, 26\u201332. https:\/\/doi.org\/10.1016\/j.ajem.2016.09.050 (2016).","journal-title":"Am. J. Emerg. Med."},{"key":"8417_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1160\/th16-05-0385","volume":"117","author":"M Schmohl","year":"2017","unstructured":"Schmohl, M. et al. Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb. Haemost. 117, 269\u2013276. https:\/\/doi.org\/10.1160\/th16-05-0385 (2017).","journal-title":"Thromb. Haemost"},{"key":"8417_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1160\/th13-07-0607","volume":"111","author":"R Herrmann","year":"2014","unstructured":"Herrmann, R. et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of Dabigatran and Rivaroxaban. Thromb. Haemost. 111, 989\u2013995. https:\/\/doi.org\/10.1160\/th13-07-0607 (2014).","journal-title":"Thromb. Haemost"},{"key":"8417_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050451","author":"NA Shnayder","year":"2021","unstructured":"Shnayder, N. A. et al. Using pharmacogenetics of direct oral anticoagulants to predict changes in their pharmacokinetics and the risk of adverse drug reactions. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines9050451 (2021).","journal-title":"Biomedicines"},{"key":"8417_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1124\/jpet.104.067660","volume":"310","author":"MH Court","year":"2004","unstructured":"Court, M. H. et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of Oxazepam glucuronidation by human liver. J. Pharmacol. Exp. Ther. 310, 656\u2013665. https:\/\/doi.org\/10.1124\/jpet.104.067660 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"8417_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","volume":"77","author":"JY Chung","year":"2005","unstructured":"Chung, J. Y. et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther. 77, 486\u2013494. https:\/\/doi.org\/10.1016\/j.clpt.2005.02.006 (2005).","journal-title":"Clin. Pharmacol. Ther."},{"key":"8417_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13318-018-0501-y","volume":"44","author":"R Padrini","year":"2019","unstructured":"Padrini, R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur. J. Drug Metab. Pharmacokinet. 44, 1\u201312. https:\/\/doi.org\/10.1007\/s13318-018-0501-y (2019).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"8417_CR34","doi-asserted-by":"publisher","first-page":"100201","DOI":"10.1016\/j.rpth.2023.100201","volume":"7","author":"S Melicine","year":"2023","unstructured":"Melicine, S. et al. Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases. Res. Pract. Thromb. Haemost. 7, 100201. https:\/\/doi.org\/10.1016\/j.rpth.2023.100201 (2023).","journal-title":"Res. Pract. Thromb. Haemost"},{"key":"8417_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/jth.13706","volume":"15","author":"A Simon","year":"2017","unstructured":"Simon, A. et al. The recommended dose of Idarucizumab May not always be sufficient for sustained reversal of Dabigatran. J. Thromb. Haemost. 15, 1317\u20131321. https:\/\/doi.org\/10.1111\/jth.13706 (2017).","journal-title":"J. Thromb. Haemost"},{"key":"8417_CR36","doi-asserted-by":"publisher","first-page":"100422","DOI":"10.1016\/j.tcr.2021.100422","volume":"32","author":"M Str\u00f6hle","year":"2021","unstructured":"Str\u00f6hle, M., Rugg, C., Schmid, S., Fries, D. & Oswald, E. Difficult reversal of Dabigatran with Idarucizumab in a multiple-trauma patient: A question of dose? Trauma. Case Rep. 32, 100422. https:\/\/doi.org\/10.1016\/j.tcr.2021.100422 (2021).","journal-title":"Trauma. Case Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08417-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T08:02:12Z","timestamp":1751788932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08417-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8417"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08417-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21967"}}